Transglutaminase 2 serves as a pathogenic hub gene of KRAS mutant colon cancer based on integrated analysis

Table 3 Chi-square tests between transglutaminase 2 level and clinicopathological characteristic in KRAS mutant patients, n (%)

Clinical parameters	TGM2 expression level		P value
	Low (n = 13)	High (n = 15)
Age			0.476
≤ 60	5 (38.46)	8 (53.33)
> 60	8 (61.54)	7 (46.67)
Gender			1.000
Female	7 (53.85)	7 (46.67)
Male	6 (46.15)	8 (53.33)
Histologic grade			1.000
Grade II	8 (61.54)	10 (66.67)
Grade III	5 (38.46)	5 (33.33)
Tumor size			0.700
< 5 cm	6 (46.15)	5 (33.33)
≥ 5 cm	7 (53.85)	10 (66.67)
Lympho-vascular invasion			0.670
No	9 (69.23)	12 (80.00)
Yes	4 (30.77)	3 (20.00)
Perineural invasion			0.044a
No	13 (100.00)	10 (66.67)
Yes	0 (0.00)	5 (33.33)
Pathologic T stage			0.445
T2-T3	7 (53.85)	5 (33.33)
T4a-T4b	6 (46.15)	10 (66.67)
Pathologic N stage			0.460
N0	9 (69.23)	8 (53.33)
N1-2	4 (30.77)	7 (46.67)
Clinical M stage			1.000
M0	13 (100.00)	14 (93.33)
M1	0 (0.00)	1 (6.67)
Disease stage			0.276
Stage I & II	9 (69.23)	7 (46.67)
Stage III & IV	4 (30.77)	8 (53.33)
CD8 positive rate			1.000
< 5%	9 (69.23)	11 (73.33)
≥ 5%	4 (30.77)	4 (26.67)
PD-L1 positive rate			1.000
< 5%	9 (69.23)	10 (66.67)
≥ 5%	4 (30.77)	5 (33.33)
PD-1 positive rate			1.000
< 5%	9 (69.23)	10 (66.67)
≥ 5%	4 (30.77)	5 (33.33)

^aP < 0.05.

TGM2: Transglutaminase 2; PD-L1: Programmed death ligand 1; PD1: Programmed cell death 1.